Takeda subsidiary Baxalta has agreed to drop its fightback against a $173 million award in favour of Bayer after an appeals court upheld a patent infringement win for the German conglomerate.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
9 June 2026 A unanimous SCOTUS ruling is being hailed as a major win for Hikma, and for delivering some welcome clarity. Experts tell Marisa Woutersen how its implications could affect pharma patent strategy across the sector.
8 June 2026 Nexus Pharmaceuticals is knocked back by the US Court of Appeals, which upholds a district court finding that it infringed a rival’s patents.
4 June 2026 Justices refuse to place generic drug makers “between a rock and a hard place,” in a landmark ruling clarifying induced patent infringement in pharma.
